anti-CD22 CAR T-cell therapy (Carsgen Therapeutics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CD22 CAR T-cell therapy (Carsgen Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsCD22 modulators
TargetsCD22
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesCarsgen Therapeutics ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCarsgen Therapeutics ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A